FREMONT, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics announced the appointment of Steven Chan as Chief Financial Officer. Mr. Chan brings extensive financial strategy and operational experience and joins Attovia after serving as Chief Financial Officer at Connect Biopharma (NASDAQ: CNTB), a global clinical-stage biopharmaceutical company focused on T cell-driven therapeutics for inflammatory diseases. At Attovia, Mr. Chan will lead the company’s finance and operations functions and serve ...

Concordia Biotech (CNTB, Financial) saw a significant increase in its stock price, rising by 5.48%. The stock is currently priced at $1.49 per share with a trading volume of 16,435 shares and a turnover rate of 0.03%. The stock's amplitude is 4.61%.According to the latest financial report, Concordia Biotech achieved a revenue of $24.12 million and a net profit of $7.65 million. The earnings per share stood at $0.14, with a gross profit of $23.64 million and a price-to-earnings ratio of -3.78.One institution ...

Announced new U.S.-based leadership with the appointment of Barry Quart, Pharm.D. as Chief Executive Officer (CEO) and David Szekeres as PresidentConnect’s new management is currently evaluating the future clinical development strategy for rademikibartAs part of Connect’s transformation into a U.S.-centric company, the Company will be significantly reducing its presence in ChinaCash and cash equivalents of $110.2 million expected to support planned operations into at least the first half of 2027 SAN DIEGO, ...

SAN DIEGO, CA and TIACANG, China, July 01, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today that Barry Quart, Chief Executive Officer, David Szekeres, President and Steven Chan, Chief Financial officer will be hosting one ...

SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today that the Board of Directors (Board), including all of the independent directors of the Board, granted to Barry Quart, Pharm.D., t ...

Industry leader Barry Quart, Pharm.D. appointed as Chief Executive Officer succeeding Zheng Wei, Ph.D., who will remain on the Board of Directors and serve as an advisor to assist with the transitionExperienced life science executive David Szekeres appointed as PresidentKleanthis G. Xanthopoulos, Ph.D. appointed as Chair of the Board of Directors SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartere ...

Industry leader Barry Quart, Pharm.D. appointed as Chief Executive Officer succeeding Zheng Wei, Ph.D., who will remain on the Board of Directors and serve as an advisor to assist with the transition Experienced life science executive David Szekeres appointed as President Kleanthis G. Xanthopoulos, Ph.D. appointed as Chair of the Board of Directors SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquarte ...

公司财务表现 - 康乃德生物通过高效的研发成果转化和商业化策略，成功实现了稳定且充裕的现金流，从而有力推动了公司的长期发展和市场竞争力的构筑 [9] - 公司的资产负债率维持在6%-9%左右，显著低于医药行业平均的30%-50%资产负债率，彰显了公司在偿债能力上的强劲实力 [14] - 公司的流动比率基本保持在10%以上，远高于普通医药行业1.5%-2%的水平，反映其在资产快速变现能力和短期偿债能力上的优势 [15] - 公司收益质量自2021年的48.4%显著增长至2023年的104.5%，显示出公司收益的稳步提升和逐渐增强的趋势 [16] - 公司在盈利能力和成长能力方面的卓越表现，充分反映其健康的经营状况和迅猛的营业利润增长 [17] 公司业务布局 - 公司采取轻资产研发为主导的模式，避免了沉重的固定资产负担、抵押贷款和外部借款，从而长期保持健康的现金流状态 [18] - 公司通过灵活运用股权融资与二级市场融资活动，确保流动资金的充沛 [19] - 公司与先声药业的商业化合作，为公司带来了充裕的现金流，为后续研发活动提供了坚实的资金保障 [9][10] - 公司通过与供应商建立长期战略合作伙伴关系，确保业务开展的连续性与稳定性，抵御外部市场风险冲击 [19] 公司核心管线布局 - 公司的管线布局包括多个临床阶段的产品，建立了具备高度差异化潜力优势的新药管线 [20] - 公司的核心产品CBP-201（乐德奇拜单抗）和CBP-307（Icanbelimod）分别针对特应性皮炎、哮喘和溃疡性结肠炎、克罗恩病等适应症 [21] 公司未来发展战略 - 公司将聚焦一带一路沿线区域的自免市场，探索第二发展曲线，对扩大全球市场份额、提振企业估值具有重要意义 [22][23] - 公司将通过与多家Pharma持续深入合作，提升在自免疾病细分赛道的自主创新能力，不断积累全球商业化经验和资金，进一步扩大市场份额和品牌影响力 [25][26] 公司团队优势 - 公司研发团队在自免疾病领域具备强大的研发能力，核心成员经验丰富、成就卓越，为公司的研发工作提供了坚实的支撑 [30][31] - 公司拥有一支创新药开发经验丰富的海归博士团队，团队平均工龄超过3年，稳定性强 [31] 乐德奇拜单抗产品竞争力 - 乐德奇拜单抗是一种高效能的抗IL-4Rα单克隆抗体，具有起效更快、用药频率更低以及更高的临床反应率的潜在临床意义 [32][33][34] - 乐德奇拜单抗在特应性皮炎和哮喘治疗领域的临床试验数据显示出优异的疗效和安全性，有望成为治疗这两种疾病的重要药物之一 [35][38][39] Icanbelimod产品竞争力 - Icanbelimod是一种高效力和高选择性的S1P1调节剂，具有更快的淋巴细胞恢复速度，提高了治疗的安全性和患者依从性 [47][49][50][51] - Icanbelimod在治疗溃疡性结肠炎方面展现出优异的疗效和安全性，有望成为同类中最佳的S1P1调节剂和UC标准治疗的重要选择 [54][55][58] 公司研发平台优势 - 公司建立了基于T细胞免疫调节功能的高通量药物筛选平台，能够快速且高效地鉴别和筛选出针对特定靶点的疾病治疗分子 [59][60][61][62] - 该创新平台为公司早期药物研发降本增效，提升了公司在药物研发领域的竞争力 [61][62]

Rademikibart treatment significantly improved lung function at Week 12; improvements were observed as early as Week 1 and sustained through Week 24Significant improvement in patient-reported asthma control occurred early and was sustained through Week 24End of Phase 2 (EoP2) meeting is scheduled with the U.S. Food and Drug Administration (FDA) for Q2 2024 SAN DIEGO, CA and TAICANG, China, May 22, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma" or the "Company") ...

SAN DIEGO, CA and TAICANG, China, May 07, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced data from its global Phase 2b trial of rademikibart in patients with moderate-to-severe asthma was accepted as a late-breaking abstract ...